Accenture Ventures, a subsidiary of global professional services firm Accenture (NYSE: ACN), has announced a strategic investment in QuantHealth, an innovative AI-powered clinical trial design company. This strategic collaboration is set to reshape the landscape of clinical trials, offering pharmaceutical and biotech companies a cutting-edge platform to advance treatment development, ensuring quicker and more cost-effective solutions for patients worldwide.
Empowering Innovation in Clinical Trials:
QuantHealth, at the forefront of AI-driven advancements, has developed a cloud-based platform that leverages artificial intelligence to simulate and optimise clinical trials. This revolutionary technology enables pharmaceutical and biotech companies to streamline the trial design process, significantly reducing both time and costs associated with treatment development.
With proprietary AI technology trained on a massive dataset of 350 million patients, large biomedical knowledge-graphs, and clinical trial data, QuantHealth’s simulation platform can predict trial outcomes with significant accuracy. It can test thousands of protocol variations and discover the optimal trial design for success, helping research and development (R&D) teams more accurately and rapidly predict clinical trial results and decide whether a trial should proceed, how to optimise cohorts, whether drugs can be repurposed, and other crucial factors.
Accelerating Treatment Development:
The strategic investment from Accenture Ventures marks a significant milestone in the evolution of clinical trial methodologies. By harnessing the power of AI, QuantHealth aims to expedite the development of treatments, facilitating a more efficient and responsive approach to addressing patient needs. This investment aligns with Accenture’s commitment to fostering technological innovation and driving positive impact in healthcare.
Key Features of QuantHealth’s Platform:
Cloud-Based Simulation: QuantHealth’s platform allows for the simulation of clinical trials in a cloud environment, providing a dynamic and flexible testing ground for pharmaceutical and biotech companies.
Cost-Effective Solutions: The AI-powered simulation enables companies to identify optimal trial designs, minimising unnecessary costs and resources while maximising the potential for successful outcomes.
Rapid Iteration: The platform allows for rapid iteration and adjustment, empowering organisations to fine-tune trial parameters in response to emerging data and insights.
Enhanced Decision-Making: By leveraging AI analytics, the platform facilitates data-driven decision-making throughout the trial design process, ensuring a more strategic and informed approach.
Strategic Vision for the Future:
Commenting on the investment, Tom Lounibos, global lead of Accenture Ventures, expressed enthusiasm about the transformative potential of this collaboration. “QuantHealth’s innovative approach to clinical trial design aligns seamlessly with our vision for the future of healthcare. We believe that investing in AI-powered solutions like QuantHealth’s platform will not only expedite treatment development but also contribute to the broader landscape of patient-centric care.”
The investment in QuantHealth reflects Accenture’s commitment to fostering groundbreaking advancements in healthcare technology. As the pharmaceutical and biotech industries continue to seek more agile and efficient methods for treatment development, AI-powered solutions are poised to play a pivotal role in shaping the future of clinical trials.
With Accenture Ventures’ strategic investment, the collaboration with QuantHealth signifies a pivotal moment in the convergence of technology and healthcare. As the industry continues to embrace innovative solutions, this partnership is set to accelerate the pace of clinical trials, ultimately translating into faster and more accessible treatments for patients around the globe. The alliance between Accenture and QuantHealth represents a bold step forward in the ongoing quest for excellence and efficiency in healthcare innovation.
Back to News + Insights